Pharsight

1. Aemcolo patent expiration

Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741948	COSMO TECHNOLOGIES	Oral antimicrobial pharmaceutical compositions	May, 2025 (8 months ago)
US8529945	COSMO TECHNOLOGIES	Oral antimicrobial pharmaceutical compositions	May, 2025 (8 months ago)
US8263120	COSMO TECHNOLOGIES	Oral antimicrobial pharmaceutical compositions	May, 2025 (8 months ago)
US8486446	COSMO TECHNOLOGIES	Oral antimicrobial pharmaceutical compositions	May, 2025 (8 months ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 16, 2023
Generating Antibiotic Incentives Now(GAIN)	Nov 16, 2028

Drugs and Companies using RIFAMYCIN SODIUM ingredient

NCE-1 date: 17 November, 2027

Market Authorisation Date: 16 November, 2018

Dosage: TABLET, DELAYED RELEASE

Strength	Dosage	Availability
EQ 194MG BASE	TABLET, DELAYED RELEASE	Discontinued

AEMCOLO family patents

2. Avelox patent expiration

Treatment: Method of combating bacteria in a patient

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6610327	BAYER HLTHCARE	Pharmaceutical moxifloxacin preparation	Oct, 2019 (6 years ago)
US5849752	BAYER HLTHCARE	Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification	Dec, 2016 (9 years ago)
US5607942	BAYER HLTHCARE	7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives	Mar, 2014 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-185)	Sep 27, 2019

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 December, 1999

Dosage: TABLET

Strength	Dosage	Availability
EQ 400MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	Discontinued

AVELOX family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Baxdela patent expiration

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults; Treating an acute bacterial skin and skin structure infection (absssi) in an overwe...

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8497378	MELINTA	Process for making quinolone compounds	Dec, 2029 (3 years from now)
US9539250	MELINTA	Salt and crystalline forms thereof of a drug	Oct, 2025 (3 months ago)
US8871938	MELINTA	Process for making quinolone compounds	Sep, 2029 (3 years from now)
US7728143	MELINTA	Salt and crystalline forms thereof of a drug	Jun, 2031 (5 years from now)
US8273892	MELINTA	Salt and crystalline forms thereof of a drug	Aug, 2026 (6 months from now)
USRE46617	MELINTA	Process for making quinolone compounds	Dec, 2029 (3 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252813	MELINTA	Salt and crystalline forms thereof of a drug	Oct, 2026 (8 months from now)
US8648093	MELINTA	Salt and crystalline forms thereof of a drug	Oct, 2025 (3 months ago)
US12036219	MELINTA	Methods of treating infections in overweight and obese patients using antibiotics	Jun, 2034 (8 years from now)
US9200088	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (3 years from now)
US9750822	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (3 years from now)
US7635773	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (3 years from now)
US8410077	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (3 years from now)
US9493582	MELINTA	Alkylated cyclodextrin compositions and processes for preparing and using the same	Feb, 2033 (7 years from now)
US12138257	MELINTA	Antimicrobial compositions	May, 2032 (6 years from now)
US8969569	MELINTA	Salt and crystalline forms thereof of a drug	Oct, 2025 (3 months ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 19, 2022
New Indication(I-815)	Oct 24, 2022
Generating Antibiotic Incentives Now(GAIN)	Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 19 June, 2026

Market Authorisation Date: 19 June, 2017

Dosage: POWDER; TABLET

Strength	Dosage	Availability
EQ 300MG BASE/VIAL	POWDER	Prescription
EQ 450MG BASE	TABLET	Prescription

BAXDELA family patents

4. Blujepa patent expiration

Treatment: Treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kg with uncomplicated urinary tract infections (uuti) caused by escherichia coli, klebsiella pneumoniae,...

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8389524	GLAXOSMITHKLINE	Tricyclic nitrogen containing compounds as antibacterial agents	Feb, 2029 (3 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 25, 2030
Generating Antibiotic Incentives Now(GAIN)	Mar 25, 2035

Drugs and Companies using GEPOTIDACIN MESYLATE ingredient

NCE-1 date: 25 March, 2034

Market Authorisation Date: 25 March, 2025

Dosage: TABLET

Strength	Dosage	Availability
EQ 750MG BASE	TABLET	Prescription

BLUJEPA family patents

5. Cubicin patent expiration

Treatment: Method of treating bacterial infections; Method for treating bacterial infection; Treatment of the following infections: complicated skin an...

Application	Filing Date	Opposition Party	Legal Status

EP10832379A	2019-04-11	Pajaro Limited	Granted and Under Opposition
EP10832379A	2019-04-10	HGF Limited	Granted and Under Opposition

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9138456	November, 2019	Institution Denied	Cubist Pharmaceuticals LLC et al.	Amneal Pharmaceuticals LLC et al.
US9138456	November, 2019	Terminated-Denied	Cubist Pharmaceuticals LLC	Amneal Pharmaceuticals LLC
US8058238	July, 2015	Terminated-Settled	Cubist Pharmaceuticals LLC	Fresenius Kabi USA LLC
US8129342	July, 2015	Terminated-Settled	Cubist Pharmaceuticals LLC	Fresenius Kabi USA LLC
US6468967	November, 2014	Final Written Decision	Cubist Pharmaceuticals LLC et al.	Fresenius-Kabi USA LLC
US6468967	November, 2014	FWD Entered	Cubist Pharmaceuticals LLC	Fresenius-Kabi USA LLC
US6852689	November, 2014	Final Written Decision	Cubist Pharmaceuticals LLC et al.	Fresenius-Kabi USA LLC
US6852689	November, 2014	FWD Entered	Cubist Pharmaceuticals LLC	Fresenius-Kabi USA LLC
US8058238	July, 2015	Institution Denied	Cubist Pharmaceuticals LLC et al.	Fresenius Kabi USA LLC
US8058238	July, 2015	Terminated-Denied	Cubist Pharmaceuticals LLC	Fresenius Kabi USA LLC
US6468967	October, 2014	Institution Denied	Cubist Pharmaceuticals, Inc. et al.	Agila Specialties Inc. et al.
US6468967	October, 2014	Terminated-Denied	Cubist Pharmaceuticals, Inc.	Agila Specialties Inc.
US6852689	October, 2014	Institution Denied	Cubist Pharmaceuticals Incorporated et al.	Agila Specialties Inc. et al.
US6852689	October, 2014	Terminated-Denied	Cubist Pharmaceuticals Incorporated	Agila Specialties Inc.
US8058238	October, 2014	Institution Denied	Cubist Pharmaceuticals, Inc. et al.	Agila Specialities Inc. et al.
US8058238	October, 2014	Terminated-Denied	Cubist Pharmaceuticals, Inc.	Agila Specialities Inc.
US8058238	October, 2014	Institution Denied	Cubist Pharmaceuticals, Inc. et al.	Agila Specialties Inc. et al.
US8058238	October, 2014	Terminated-Denied	Cubist Pharmaceuticals, Inc.	Agila Specialties Inc.
US8129342	October, 2014	Institution Denied	Cubist Pharmaceuticals, Inc. et al.	Agila Specialities Inc. et al.
US8129342	October, 2014	Terminated-Denied	Cubist Pharmaceuticals, Inc.	Agila Specialities Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138456	CUBIST PHARMS LLC	Lipopeptide compositions and related methods	Nov, 2030 (4 years from now)
US6468967	CUBIST PHARMS LLC	Methods for administration of antibiotics	Sep, 2019 (6 years ago)
US8058238	CUBIST PHARMS LLC	High purity lipopeptides	Nov, 2020 (5 years ago)
US6852689	CUBIST PHARMS LLC	Methods for administration of antibiotics	Sep, 2019 (6 years ago)
US8129342	CUBIST PHARMS LLC	High purity lipopeptides	Nov, 2020 (5 years ago)
USRE39071	CUBIST PHARMS LLC	Anhydro-and isomer-a-21978c cyclic peptides	Jun, 2016 (9 years ago)
US8003673	CUBIST PHARMS LLC	Daptomycin for the treatment of biofilm and catheter salvage	Sep, 2028 (2 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Mar 29, 2020
M(M-211)	Sep 01, 2020

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 12 September, 2003

Dosage: POWDER

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
500 mg/vial	19 Nov, 2008	1			Extinguished

Strength	Dosage	Availability
500MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER	Discontinued
250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	POWDER	Discontinued

CUBICIN family patents

6. Doribax patent expiration

Treatment: Method of treating bacterial infections

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8247402	SHIONOGI INC	Crystal form of pyrrolidylthiocarbapenem derivative	Mar, 2021 (4 years ago)
US5317016	SHIONOGI INC	Pyrrolidylthiocarbapenem derivative	Jun, 2015 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 12, 2012

Drugs and Companies using DORIPENEM ingredient

NCE-1 date: 13 October, 2011

Market Authorisation Date: 05 October, 2010

Dosage: INJECTABLE

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
250 mg/vial and 500 mg/vial	12 Oct, 2011	1		05 Jun, 2015	Extinguished

Strength	Dosage	Availability
500MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE	Discontinued
250MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	INJECTABLE	Discontinued

DORIBAX family patents

7. Fetroja patent expiration

Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9238657	SHIONOGI INC	Cephalosporin having catechol group	Nov, 2033 (7 years from now)
US10004750	SHIONOGI INC	Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof	Sep, 2035 (9 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982	SHIONOGI INC	Preparation containing cephalosporin having a catechol moiety	Sep, 2035 (9 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-844)	Sep 25, 2023
New Chemical Entity Exclusivity(NCE)	Nov 14, 2024
Generating Antibiotic Incentives Now(GAIN)	Nov 14, 2029

Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient

NCE-1 date: 14 November, 2028

Market Authorisation Date: 14 November, 2019

Dosage: POWDER

Strength	Dosage	Availability
EQ 1GM BASE/VIAL	POWDER	Prescription

FETROJA family patents

8. Invanz patent expiration

Treatment: Treatment of bacterial infectious disease

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5478820 (Pediatric)	MSD SUB MERCK	Antibiotic compounds	May, 2016 (9 years ago)
US5652233	MSD SUB MERCK	Antibiotic compounds	Feb, 2013 (12 years ago)
US5952323 (Pediatric)	MSD SUB MERCK	Carbapenem antibiotic	Nov, 2017 (8 years ago)
US7342005	MSD SUB MERCK	Antibiotic compounds	Feb, 2013 (12 years ago)
US7342005 (Pediatric)	MSD SUB MERCK	Antibiotic compounds	Aug, 2013 (12 years ago)
US5652233 (Pediatric)	MSD SUB MERCK	Antibiotic compounds	Aug, 2013 (12 years ago)
US5478820	MSD SUB MERCK	Antibiotic compounds	Nov, 2015 (10 years ago)
US5952323	MSD SUB MERCK	Carbapenem antibiotic	May, 2017 (8 years ago)

Drugs and Companies using ERTAPENEM SODIUM ingredient

Market Authorisation Date: 21 November, 2001

Dosage: INJECTABLE

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 g/vial	21 Dec, 2012	1		15 May, 2017	Extinguished

Strength	Dosage	Availability
EQ 1GM BASE/VIAL	INJECTABLE	Prescription

INVANZ family patents

9. Ketek patent expiration

Treatment: Treatment of community acquired pneumonia, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis caused by susceptible strains of designated microorganisms in patients 18 years and o...

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USD459798	SANOFI AVENTIS US	Pill tablet	Sep, 2015 (10 years ago)
US5635485	SANOFI AVENTIS US	Erythromycin compounds	Apr, 2018 (7 years ago)

Drugs and Companies using TELITHROMYCIN ingredient

Market Authorisation Date: 01 April, 2004

Dosage: TABLET

Strength	Dosage	Availability
400MG	TABLET	Discontinued
300MG	TABLET	Discontinued

KETEK family patents

10. Nuzyra patent expiration

Treatment: Treatment of bacterial skin and skin structure infections; Treatment of community acquired bacterial pneumonia; Treatment of subjects having bacterial skin or skin structure infection; Treatment of ba...

Application	Filing Date	Opposition Party	Legal Status

EP18158017A	2021-05-28	Lederer & Keller Patentanwälte Partnerschaft mbB	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326696	PARATEK PHARMS	Amino-methyl substituted tetracycline compounds	Sep, 2023 (2 years ago)
US7553828	PARATEK PHARMS	9-aminomethyl substituted minocycline compounds	Jun, 2025 (7 months ago)
US8383610	PARATEK PHARMS	Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline	Sep, 2030 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9365500	PARATEK PHARMS	9-aminomethyl substituted minocycline compounds	Jun, 2021 (4 years ago)
US10383884	PARATEK PHARMS	9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)	Oct, 2037 (11 years from now)
US9724358	PARATEK PHARMS	Minocycline compounds and methods of use thereof	Mar, 2029 (3 years from now)
US10111890	PARATEK PHARMS	9-aminomethyl minocycline compounds and uses thereof	Aug, 2037 (11 years from now)
US10124014	PARATEK PHARMS	Minocycline compounds and methods of use thereof	Mar, 2029 (3 years from now)
US10835542	PARATEK PHARMS	9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)	Oct, 2037 (11 years from now)
US9265740	PARATEK PHARMS	Minocycline compounds and methods of use thereof	Mar, 2029 (3 years from now)
US9314475	PARATEK PHARMS	Oral and injectable formulations of tetracycline compounds	Mar, 2031 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 02, 2023
Generating Antibiotic Incentives Now(GAIN)	Oct 02, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 03 October, 2027

Market Authorisation Date: 02 October, 2018

Dosage: TABLET; POWDER

Strength	Dosage	Availability
EQ 150MG BASE	TABLET	Prescription
EQ 100MG BASE/VIAL	POWDER	Prescription

NUZYRA family patents

11. Orbactiv patent expiration

Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections

Application	Filing Date	Opposition Party	Legal Status

EP09810708A	2017-01-13	Prüfer & Partner mbB	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5840684	MELINTA THERAP	Glycopeptide antibiotic derivatives	Nov, 2020 (5 years ago)
US5998581	MELINTA THERAP	Reductive alkylation of glycopeptide antibiotics	Nov, 2017 (8 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592	MELINTA THERAP	Methods of treatment using single doses of oritavancin	Aug, 2029 (3 years from now)
US9682061	MELINTA THERAP	Methods of treating bacterial infections using oritavancin	Apr, 2030 (4 years from now)
US9649352	MELINTA THERAP	High purity oritavancin and method of producing same	Jul, 2035 (9 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 06, 2019
Generating Antibiotic Incentives Now(GAIN)	Aug 06, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 07 August, 2023

Market Authorisation Date: 06 August, 2014

Dosage: POWDER

Strength	Dosage	Availability
EQ 400MG BASE/VIAL	POWDER	Prescription

ORBACTIV family patents

12. Sivextro patent expiration

Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated...

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8426389	CUBIST PHARMS LLC	Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate	Dec, 2030 (4 years from now)
US8420676	CUBIST PHARMS LLC	Oxazolidinone derivatives	Feb, 2028 (2 years from now)
US7816379	CUBIST PHARMS LLC	Oxazolidinone derivatives	Jun, 2028 (2 years from now)
US9624250	CUBIST PHARMS LLC	Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate	Feb, 2030 (4 years from now)
US10442829	CUBIST PHARMS LLC	Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate	Feb, 2030 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9988406	CUBIST PHARMS LLC	Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate	Feb, 2030 (4 years from now)
US10065947	CUBIST PHARMS LLC	Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate	Feb, 2030 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 20, 2019
Generating Antibiotic Incentives Now(GAIN)	Jun 20, 2024
New Patient Population(NPP)	Apr 04, 2028

Drugs and Companies using TEDIZOLID PHOSPHATE ingredient

NCE-1 date: 21 June, 2023

Market Authorisation Date: 20 June, 2014

Dosage: TABLET; POWDER

Strength	Dosage	Availability
200MG	TABLET	Prescription
200MG/VIAL	POWDER	Prescription

SIVEXTRO family patents

13. Solosec patent expiration

Treatment: Treatment of trichomoniasis in patients 12 years of age and older; Treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of bacterial vaginosis in adult women

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12280037	EVOFEM INC	Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof	Dec, 2041 (15 years from now)
US10335390	EVOFEM INC	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (9 years from now)
US11602522	EVOFEM INC	Secnidazole for use in the treatment of sexually transmitted infection	Sep, 2035 (9 years from now)
US10849884	EVOFEM INC	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (9 years from now)
US10857133	EVOFEM INC	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (9 years from now)
US11000508	EVOFEM INC	Secnidazole for use in the treatment of trichomoniasis	Sep, 2035 (9 years from now)
US11000507	EVOFEM INC	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (9 years from now)
US11020377	EVOFEM INC	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (9 years from now)
US10682338	EVOFEM INC	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (9 years from now)
US11684607	EVOFEM INC	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (9 years from now)
US11324721	EVOFEM INC	Secnidazole for use in the treatment of trichomoniasis	Sep, 2035 (9 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 15, 2022
New Indication(I-866)	Jun 30, 2024
New Patient Population(NPP)	Jan 26, 2025
Generating Antibiotic Incentives Now(GAIN)	Sep 15, 2027

Drugs and Companies using SECNIDAZOLE ingredient

NCE-1 date: 15 September, 2026

Market Authorisation Date: 15 September, 2017

Dosage: GRANULE

Strength	Dosage	Availability
2GM/PACKET	GRANULE	Prescription

SOLOSEC family patents

14. Spectracef patent expiration

Treatment: NA

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5958915	VANSEN PHARMA	Antibacterial composition for oral administration	Oct, 2016 (9 years ago)

Drugs and Companies using CEFDITOREN PIVOXIL ingredient

Market Authorisation Date: 29 August, 2001

Dosage: TABLET

Strength	Dosage	Availability
400MG	TABLET	Discontinued
200MG	TABLET	Discontinued

SPECTRACEF family patents

15. Tygacil patent expiration

Treatment: Method of treating bacterial infections

Application	Filing Date	Opposition Party	Legal Status

EP06737947A	2014-06-11	Hollatz, Christian	Patent maintained as amended
EP06737947A	2014-06-11	Hollatz, Christian	Patent maintained as amended
EP06737947A	2014-06-11	PENTAFARMA S.A.	Patent maintained as amended
EP06737947A	2014-06-10	df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB	Patent maintained as amended
EP06760544A	2014-01-24	Taylor Wessing LLP	Revoked
EP06760544A	2014-01-24	Galenicum Health S.L.	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7879828	March, 2015	Institution Denied	Wyeth LLC	Apotex Inc. et al.
US7879828	March, 2015	Terminated-Denied	Wyeth LLC	Apotex Inc.
US7879828	November, 2013	Final Written Decision	Wyeth LLC et al.	Apotex Inc. et al.
US7879828	November, 2013	FWD Entered	Wyeth LLC	Apotex Inc.
US7879828	August, 2014	Institution Denied	Wyeth LLC et al.	Initiative for Responsibility in Drug Pricing LLC
US7879828	August, 2014	Terminated-Denied	Wyeth LLC	Initiative for Responsibility in Drug Pricing LLC

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE40183	PF PRISM CV	7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines	Apr, 2016 (9 years ago)
USRE40086	PF PRISM CV	Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines	Jun, 2013 (12 years ago)
US7879828	PF PRISM CV	Tigecycline compositions and methods of preparation	Feb, 2029 (3 years from now)
US9254328	PF PRISM CV	Tigecycline compositions and methods of preparation	Mar, 2026 (2 months from now)
US8975242	PF PRISM CV	Tigecycline compositions and methods of preparation	Oct, 2028 (2 years from now)
US8372995	PF PRISM CV	Crystalline solid forms of tigecycline and methods of preparing same	Oct, 2030 (4 years from now)
US10588975	PF PRISM CV	Tigecycline compositions and methods of preparation	Mar, 2026 (2 months from now)
US9694078	PF PRISM CV	Tigecycline compositions and methods of preparation	Mar, 2026 (2 months from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-586)	Mar 20, 2012
New Indication(I-587)	Mar 20, 2012
New Indication(I-588)	Mar 20, 2012

Drugs and Companies using TIGECYCLINE ingredient

Market Authorisation Date: 15 June, 2005

Dosage: POWDER

TYGACIL family patents

16. Vibativ patent expiration

Treatment: Method for treating bacterial infection; Method of treating a staphylococcal infection; Method of treating bacterial infections

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7531623	CUMBERLAND	Hydrochloride salts of a glycopeptide phosphonate derivative	Jan, 2027 (11 months from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7544364	CUMBERLAND	Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin	May, 2021 (4 years ago)
US6872701	CUMBERLAND	Glycopeptide phosphonate derivatives	Jun, 2021 (4 years ago)
US8158580	CUMBERLAND	Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin	May, 2021 (4 years ago)
US6635618	CUMBERLAND	Glycopeptide phosphonate derivatives	Sep, 2023 (2 years ago)
US7008923	CUMBERLAND	Glycopeptide phosphonate derivatives	May, 2021 (4 years ago)
US7700550	CUMBERLAND	Glycopeptide phosphonate derivatives	May, 2021 (4 years ago)
US7208471	CUMBERLAND	Glycopeptide phosphonate derivatives	May, 2021 (4 years ago)
US8101575	CUMBERLAND	Glycopeptide phosphonate derivatives	May, 2021 (4 years ago)
US6858584	CUMBERLAND	Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin	Aug, 2022 (3 years ago)
US7351691	CUMBERLAND	Glycopeptide phosphonate derivatives	May, 2021 (4 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 11, 2014
New Indication(I-673)	Jun 21, 2016

Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient

NCE-1 date: 11 September, 2013

Market Authorisation Date: 11 September, 2009

Dosage: POWDER

VIBATIV family patents

17. Xenleta patent expiration

Treatment: Treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6753445	HONG KONG	Pleuromutilin derivatives having antibacterial activity	Jul, 2021 (4 years ago)
US8071643	HONG KONG	Pleuromutilin derivatives for the treatment of diseases mediated by microbes	Mar, 2033 (7 years from now)
US8153689	HONG KONG	Pleuromutilin derivatives for the treatment of diseases mediated by microbes	Mar, 2028 (2 years from now)
US9120727	HONG KONG	Process for the preparation of pleuromutilins	May, 2031 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12121582	HONG KONG	Injectable pharmaceutical formulations of lefamulin	Jun, 2036 (10 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 19, 2024
Generating Antibiotic Incentives Now(GAIN)	Aug 19, 2029

Drugs and Companies using LEFAMULIN ACETATE ingredient

NCE-1 date: 19 August, 2028

Market Authorisation Date: 19 August, 2019

Dosage: TABLET; SOLUTION

XENLETA family patents

18. Xifaxan patent expiration

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; ...

Application	Filing Date	Opposition Party	Legal Status

EP09818544A	2020-09-11	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP09818544A	2020-09-11	Hollatz, Christian	Granted and Under Opposition
EP09818544A	2020-09-11	STADA Arzneimittel AG	Granted and Under Opposition
EP09818544A	2020-09-09	Accord Healthcare Ltd	Granted and Under Opposition
EP09818544A	2020-09-09	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP09818544A	2020-09-07	Aera A/S	Granted and Under Opposition
EP09818544A	2020-08-31	Lederer & Keller Patentanwälte Partnerschaft mbB	Granted and Under Opposition
EP09818544A	2020-08-06	CMS Cameron McKenna Nabarro Olswang LLP	Granted and Under Opposition
EP09715020A	2019-12-19	Lederer & Keller Patentanwälte Partnerschaft mbB	Granted and Under Opposition
EP09715020A	2019-12-19	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP09715020A	2019-12-18	Sandoz GmbH	Granted and Under Opposition
EP05004695A	2015-06-03	Sandoz GmbH	Revoked
EP04005541A	2008-02-08	Interquim, S.A. De C.V.	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8741904	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (a month from now)
US8835452	SALIX PHARMS	Polymorphic forms α, β and γ of rifaximin	Jun, 2024 (1 year, 6 months ago)
US8193196	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Sep, 2027 (1 year, 7 months from now)
US8158781	SALIX PHARMS	Polymorphic forms α, β and γ of rifaximin	Jun, 2024 (1 year, 6 months ago)
US7612199	SALIX PHARMS	Polymorphic forms α, β, and γ of rifaximin	Jun, 2024 (1 year, 6 months ago)
US7902206	SALIX PHARMS	Polymorphic forms α, β and γ of rifaximin	Jun, 2024 (1 year, 6 months ago)
US7045620	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations	Jun, 2024 (1 year, 6 months ago)
US7906542	SALIX PHARMS	Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin	Jun, 2025 (7 months ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456384	SALIX PHARMS	Methods for treating irritable bowel syndrome (IBS)	Feb, 2029 (3 years from now)
US10335397	SALIX PHARMS	Methods of treating hepatic encephalopathy	Jul, 2029 (3 years from now)
US9421195	SALIX PHARMS	Methods of treating hepatic encephalopathy	Jul, 2029 (3 years from now)
US8946252	SALIX PHARMS	Methods of treating traveler's diarrhea and hepatic encephalopathy	Jul, 2029 (3 years from now)
US7452857	SALIX PHARMS	Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth	Aug, 2019 (6 years ago)
US8829017	SALIX PHARMS	Methods of treating traveler's diarrhea and hepatic encephalopathy	Jul, 2029 (3 years from now)
US8642573	SALIX PHARMS	Methods of treating hepatic encephalopathy	Oct, 2029 (3 years from now)
US10314828	SALIX PHARMS	Methods of treating hepatic encephalopathy	Jul, 2029 (3 years from now)
US7915275	SALIX PHARMS	Use of polymorphic forms of rifaximin for medical preparations	Feb, 2025 (10 months ago)
US7605240	SALIX PHARMS	Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth	Aug, 2019 (6 years ago)
US7935799	SALIX PHARMS	Methods of treating diarrhea caused by small intestinal bacterial overgrowth	Aug, 2019 (6 years ago)
US10709694	SALIX PHARMS	Methods of treating hepatic encephalopathy	Jul, 2029 (3 years from now)
US10765667	SALIX PHARMS	Methods for treating irritable bowel syndrome (IBS)	Feb, 2029 (3 years from now)
US8969398	SALIX PHARMS	Methods of treating hepatic encephalopathy	Oct, 2029 (3 years from now)
US6861053	SALIX PHARMS	Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth	Aug, 2019 (6 years ago)
US8518949	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (a month from now)
US9629828	SALIX PHARMS	Methods of treating traveler's diarrhea and hepatic encephalopathy	Jul, 2029 (3 years from now)
US9271968	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (a month from now)
US8158781	SALIX PHARMS	Polymorphic forms α, β and γ of rifaximin	Jun, 2024 (1 year, 6 months ago)
US8158644	SALIX PHARMS	Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin	Jun, 2024 (1 year, 6 months ago)
US7612199	SALIX PHARMS	Polymorphic forms α, β, and γ of rifaximin	Jun, 2024 (1 year, 6 months ago)
US8853231	SALIX PHARMS	Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin	Jun, 2024 (1 year, 6 months ago)
US7045620	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations	Jun, 2024 (1 year, 6 months ago)
US8193196	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Sep, 2027 (1 year, 7 months from now)
US10703763	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (a month from now)
US7718608	SALIX PHARMS	Methods of treating a subject suffering from irritable bowel syndrome	Aug, 2019 (6 years ago)
US8309569	SALIX PHARMS	Methods for treating diarrhea-associated irritable bowel syndrome	Jul, 2029 (3 years from now)
US7902206	SALIX PHARMS	Polymorphic forms α, β and γ of rifaximin	Jun, 2024 (1 year, 6 months ago)
US7906542	SALIX PHARMS	Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin	Jun, 2025 (7 months ago)
US7928115	SALIX PHARMS	Methods of treating travelers diarrhea and hepatic encephalopathy	Jul, 2029 (3 years from now)
US11779571	SALIX PHARMS	Methods for treating irritable bowel syndrome (IBS)	Feb, 2029 (3 years from now)
US11564912	SALIX PHARMS	Methods for treating irritable bowel syndrome (IBS)	Feb, 2029 (3 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 24, 2013
Orphan Drug Exclusivity(ODE)	Mar 24, 2017
New Indication(I-709)	May 27, 2018

Drugs and Companies using RIFAXIMIN ingredient

Market Authorisation Date: 24 March, 2010

Dosage: TABLET

XIFAXAN family patents

19. Zemdri patent expiration

Treatment: Method of using plazomicin to treat bacterial infections

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8383596	CIPLA USA	Antibacterial aminoglycoside analogs	Jun, 2031 (5 years from now)
US9688711	CIPLA USA	Antibacterial aminoglycoside analogs	Nov, 2028 (2 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9266919	CIPLA USA	Antibacterial aminoglycoside analogs	Nov, 2028 (2 years from now)
US8822424	CIPLA USA	Antibacterial aminoglycoside analogs	Nov, 2028 (2 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 25, 2023
Generating Antibiotic Incentives Now(GAIN)	Jun 25, 2028

Drugs and Companies using PLAZOMICIN SULFATE ingredient

NCE-1 date: 26 June, 2027

Market Authorisation Date: 25 June, 2018

Dosage: SOLUTION

ZEMDRI family patents

20. Zyvox patent expiration

Treatment: Treatment of microbial infections

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6559305	PFIZER	Linezolid—crystal form II	Jan, 2021 (4 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6514529	PFIZER	Oxazolidinone tablet formulation	Mar, 2021 (4 years ago)
US6559305	PFIZER	Linezolid—crystal form II	Jan, 2021 (4 years ago)
US6559305 (Pediatric)	PFIZER	Linezolid—crystal form II	Jul, 2021 (4 years ago)
US5688792	PFIZER	Substituted oxazine and thiazine oxazolidinone antimicrobials	Nov, 2014 (11 years ago)
US5688792 (Pediatric)	PFIZER	Substituted oxazine and thiazine oxazolidinone antimicrobials	May, 2015 (10 years ago)
US6514529 (Pediatric)	PFIZER	Oxazolidinone tablet formulation	Sep, 2021 (4 years ago)

Drugs and Companies using LINEZOLID ingredient

Market Authorisation Date: 18 April, 2000

Dosage: SOLUTION; TABLET; FOR SUSPENSION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
550 mg	18 Dec, 2015	1		02 Oct, 2029	Non-Forfeiture
200 mg	28 Jan, 2019	1		24 Jul, 2029

Strength	Dosage	Availability
EQ 750MG BASE/VIAL	POWDER	Prescription
EQ 250MG BASE/VIAL	POWDER	Discontinued

Strength	Dosage	Availability
EQ 600MG BASE	TABLET	Prescription
EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	SOLUTION	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2 mg/mL, 100 mL bag	29 Dec, 2009	1	16 Jul, 2015	18 Nov, 2014	Extinguished
2 mg/mL, 300 mL bag	01 Sep, 2009	1	27 Jun, 2012	18 Nov, 2014	Deferred
100 mg/5 mL	03 Aug, 2009	1	03 Jun, 2015	29 Jan, 2021	Deferred
600 mg	21 Dec, 2005	1	18 May, 2015	18 Nov, 2014	Eligible

Strength	Dosage	Availability
600MG/300ML (2MG/ML)	SOLUTION	Prescription
600MG	TABLET	Discontinued
200MG/100ML (2MG/ML)	SOLUTION	Prescription
400MG/200ML (2MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION	Discontinued
400MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	Discontinued
100MG/5ML	FOR SUSPENSION	Prescription

Pharsight

Pharsight

Bacterial Infections Therapeutics

1. Aemcolo patent expiration

AEMCOLO family patents

2. Avelox patent expiration

AVELOX family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years. Get the exclusive patent insights now. Don't be the last to know. Download Report 3. Baxdela patent expiration

BAXDELA family patents

4. Blujepa patent expiration

BLUJEPA family patents

5. Cubicin patent expiration

CUBICIN family patents

6. Doribax patent expiration

DORIBAX family patents

7. Fetroja patent expiration

FETROJA family patents

8. Invanz patent expiration

INVANZ family patents

9. Ketek patent expiration

KETEK family patents

10. Nuzyra patent expiration

NUZYRA family patents

11. Orbactiv patent expiration

ORBACTIV family patents

12. Sivextro patent expiration

SIVEXTRO family patents

13. Solosec patent expiration

SOLOSEC family patents

14. Spectracef patent expiration

SPECTRACEF family patents

15. Tygacil patent expiration

TYGACIL family patents

16. Vibativ patent expiration

VIBATIV family patents

17. Xenleta patent expiration

XENLETA family patents

18. Xifaxan patent expiration

XIFAXAN family patents

19. Zemdri patent expiration

ZEMDRI family patents

20. Zyvox patent expiration

ZYVOX family patents

Related content

Have Questions?

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Baxdela patent expiration